Amgen Inc. Logo

Amgen Inc.

AMGN

(3.2)
Stock Price

263,38 USD

7.43% ROA

68.49% ROE

54.5x PER

Market Cap.

170.698.676.720,00 USD

1057.3% DER

2.8% Yield

13.04% NPM

Amgen Inc. Stock Analysis

Amgen Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Amgen Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (129.08%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 Revenue Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

4 Dividend Growth

The company has demonstrated exceptional dividend growth over the past five years, consistently increasing payouts to shareholders year after year.

5 Dividend

Investors can take comfort in the company's unwavering commitment to dividends, as it has consistently distributed payouts over the past five years, ensuring a reliable income stream.

6 Net Profit Growth

Throughout the last three years, this company has experienced consistent net profit growth, reflecting a robust financial performance and making it an attractive investment prospect.

7 Assets Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

8 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (948), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

9 PBV

The stock's high Price-to-Book Value (P/BV) ratio (18.55x) suggests it's overvalued, potentially making it an expensive investment.

10 DER

The stock is burdened with a heavy load of debt (790%), making it financially unstable and potentially risky for investors.

11 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

Amgen Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Amgen Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Amgen Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Amgen Inc. Revenue
Year Revenue Growth
1985 21.100.000
1986 29.800.000 29.19%
1987 44.300.000 32.73%
1988 70.200.000 36.89%
1990 190.400.000 63.13%
1990 190.400.000 0%
1991 679.800.000 71.99%
1992 1.080.300.000 37.07%
1993 1.354.900.000 20.27%
1994 1.620.000.000 16.36%
1995 1.903.800.000 14.91%
1996 2.198.100.000 13.39%
1997 2.345.700.000 6.29%
1998 2.642.300.000 11.23%
1999 3.204.200.000 17.54%
2000 3.448.400.000 7.08%
2001 4.015.700.000 14.13%
2002 5.523.000.000 27.29%
2003 8.356.000.000 33.9%
2004 10.550.000.000 20.8%
2005 12.430.000.000 15.12%
2006 14.268.000.000 12.88%
2007 14.771.000.000 3.41%
2008 15.003.000.000 1.55%
2009 14.642.000.000 -2.47%
2010 15.053.000.000 2.73%
2011 15.582.000.000 3.39%
2012 17.265.000.000 9.75%
2013 18.676.000.000 7.56%
2014 20.063.000.000 6.91%
2015 21.662.000.000 7.38%
2016 22.991.000.000 5.78%
2017 22.849.000.000 -0.62%
2018 23.747.000.000 3.78%
2019 23.362.000.000 -1.65%
2020 25.424.000.000 8.11%
2021 25.979.000.000 2.14%
2022 26.323.000.000 1.31%
2023 27.612.000.000 4.67%
2023 28.190.000.000 2.05%
2024 33.332.000.000 15.43%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Amgen Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1990 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 323.600.000 100%
1995 451.700.000 28.36%
1996 528.300.000 14.5%
1997 630.800.000 16.25%
1998 663.300.000 4.9%
1999 822.800.000 19.39%
2000 845.000.000 2.63%
2001 865.000.000 2.31%
2002 1.116.600.000 22.53%
2003 1.655.400.000 32.55%
2004 2.028.000.000 18.37%
2005 2.314.000.000 12.36%
2006 3.366.000.000 31.25%
2007 3.266.000.000 -3.06%
2008 3.030.000.000 -7.79%
2009 2.864.000.000 -5.8%
2010 2.894.000.000 1.04%
2011 3.167.000.000 8.62%
2012 3.380.000.000 6.3%
2013 4.083.000.000 17.22%
2014 4.297.000.000 4.98%
2015 4.070.000.000 -5.58%
2016 3.840.000.000 -5.99%
2017 3.562.000.000 -7.8%
2018 3.737.000.000 4.68%
2019 4.116.000.000 9.21%
2020 4.207.000.000 2.16%
2021 4.819.000.000 12.7%
2022 4.434.000.000 -8.68%
2023 4.316.000.000 -2.73%
2023 4.784.000.000 9.78%
2024 5.788.000.000 17.35%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Amgen Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1985 22.000.000
1986 6.800.000 -223.53%
1987 10.300.000 33.98%
1988 23.000.000 55.22%
1990 134.600.000 82.91%
1990 134.600.000 0%
1991 0 0%
1992 397.400.000 100%
1993 583.700.000 31.92%
1994 359.800.000 -62.23%
1995 418.400.000 14.01%
1996 470.600.000 11.09%
1997 483.800.000 2.73%
1998 515.400.000 6.13%
1999 654.300.000 21.23%
2000 826.900.000 20.87%
2001 970.700.000 14.81%
2002 1.462.100.000 33.61%
2003 1.952.600.000 25.12%
2004 2.556.000.000 23.61%
2005 2.790.000.000 8.39%
2006 3.366.000.000 17.11%
2007 3.361.000.000 -0.15%
2008 3.789.000.000 11.3%
2009 3.820.000.000 0.81%
2010 3.983.000.000 4.09%
2011 4.486.000.000 11.21%
2012 4.801.000.000 6.56%
2013 5.184.000.000 7.39%
2014 4.699.000.000 -10.32%
2015 4.846.000.000 3.03%
2016 5.062.000.000 4.27%
2017 4.870.000.000 -3.94%
2018 5.332.000.000 8.66%
2019 4.361.000.000 -22.27%
2020 4.768.000.000 8.54%
2021 4.525.000.000 -5.37%
2022 4.573.000.000 1.05%
2023 0 0%
2023 5.532.000.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Amgen Inc. EBITDA
Year EBITDA Growth
1985 3.100.000
1986 -1.800.000 272.22%
1987 -9.500.000 81.05%
1988 5.300.000 279.25%
1990 37.500.000 85.87%
1990 37.500.000 0%
1991 109.000.000 65.6%
1992 466.600.000 76.64%
1993 554.500.000 15.85%
1994 871.200.000 36.35%
1995 796.100.000 -9.43%
1996 963.800.000 17.4%
1997 1.112.600.000 13.37%
1998 1.146.200.000 2.93%
1999 1.333.700.000 14.06%
2000 1.404.000.000 5.01%
2001 1.750.200.000 19.78%
2002 12.597.100.000 86.11%
2003 3.758.000.000 -235.21%
2004 5.190.000.000 27.59%
2005 5.738.000.000 9.55%
2006 7.265.000.000 21.02%
2007 7.299.000.000 0.47%
2008 6.667.000.000 -9.48%
2009 6.076.000.000 -9.73%
2010 6.215.000.000 2.24%
2011 5.054.000.000 -22.97%
2012 6.356.000.000 20.48%
2013 6.287.000.000 -1.1%
2014 6.656.000.000 5.54%
2015 9.073.000.000 26.64%
2016 10.423.000.000 12.95%
2017 10.901.000.000 4.38%
2018 10.937.000.000 0.33%
2019 10.427.000.000 -4.89%
2020 9.395.000.000 -10.98%
2021 9.403.000.000 0.09%
2022 8.752.000.000 -7.44%
2023 10.824.000.000 19.14%
2023 14.801.000.000 26.87%
2024 13.016.000.000 -13.71%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Amgen Inc. Gross Profit
Year Gross Profit Growth
1985 23.600.000
1986 8.000.000 -195%
1987 8.800.000 9.09%
1988 26.200.000 66.41%
1990 175.700.000 85.09%
1990 175.700.000 0%
1991 588.600.000 70.15%
1992 929.100.000 36.65%
1993 1.185.600.000 21.63%
1994 1.456.400.000 18.59%
1995 1.715.100.000 15.08%
1996 2.015.200.000 14.89%
1997 2.162.000.000 6.79%
1998 2.440.900.000 11.43%
1999 2.978.900.000 18.06%
2000 3.251.800.000 8.39%
2001 3.572.700.000 8.98%
2002 4.787.300.000 25.37%
2003 7.015.300.000 31.76%
2004 8.819.000.000 20.45%
2005 10.348.000.000 14.78%
2006 12.173.000.000 14.99%
2007 12.223.000.000 0.41%
2008 12.707.000.000 3.81%
2009 12.551.000.000 -1.24%
2010 12.833.000.000 2.2%
2011 13.155.000.000 2.45%
2012 14.347.000.000 8.31%
2013 15.330.000.000 6.41%
2014 15.641.000.000 1.99%
2015 17.435.000.000 10.29%
2016 18.829.000.000 7.4%
2017 18.780.000.000 -0.26%
2018 19.646.000.000 4.41%
2019 19.006.000.000 -3.37%
2020 19.265.000.000 1.34%
2021 19.525.000.000 1.33%
2022 19.917.000.000 1.97%
2023 20.388.000.000 2.31%
2023 19.739.000.000 -3.29%
2024 20.388.000.000 3.18%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Amgen Inc. Net Profit
Year Net Profit Growth
1985 500.000
1986 800.000 37.5%
1987 1.700.000 52.94%
1988 -8.200.000 120.73%
1990 19.100.000 142.93%
1990 19.100.000 0%
1991 97.900.000 80.49%
1992 357.600.000 72.62%
1993 383.300.000 6.7%
1994 319.700.000 -19.89%
1995 537.700.000 40.54%
1996 679.800.000 20.9%
1997 644.300.000 -5.51%
1998 863.200.000 25.36%
1999 1.096.400.000 21.27%
2000 1.138.500.000 3.7%
2001 1.119.700.000 -1.68%
2002 -1.391.900.000 180.44%
2003 2.259.500.000 161.6%
2004 2.363.000.000 4.38%
2005 3.674.000.000 35.68%
2006 2.950.000.000 -24.54%
2007 3.166.000.000 6.82%
2008 4.196.000.000 24.55%
2009 4.605.000.000 8.88%
2010 4.627.000.000 0.48%
2011 3.683.000.000 -25.63%
2012 4.345.000.000 15.24%
2013 5.081.000.000 14.49%
2014 5.158.000.000 1.49%
2015 6.939.000.000 25.67%
2016 7.722.000.000 10.14%
2017 1.979.000.000 -290.2%
2018 8.394.000.000 76.42%
2019 7.842.000.000 -7.04%
2020 7.264.000.000 -7.96%
2021 5.893.000.000 -23.26%
2022 6.552.000.000 10.06%
2023 6.920.000.000 5.32%
2023 6.717.000.000 -3.02%
2024 2.984.000.000 -125.1%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Amgen Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1990 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 1 0%
1997 1 0%
1998 1 0%
1999 1 100%
2000 1 0%
2001 1 0%
2002 -1 200%
2003 2 200%
2004 2 0%
2005 3 50%
2006 3 0%
2007 3 0%
2008 4 33.33%
2009 5 25%
2010 5 0%
2011 4 0%
2012 6 20%
2013 7 16.67%
2014 7 0%
2015 9 33.33%
2016 10 10%
2017 3 -400%
2018 13 83.33%
2019 13 0%
2020 12 0%
2021 10 -20%
2022 12 16.67%
2023 13 0%
2023 13 0%
2024 6 -140%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Amgen Inc. Free Cashflow
Year Free Cashflow Growth
1988 -49.100.000
1989 -25.400.000 -93.31%
1990 -51.400.000 50.58%
1991 102.400.000 150.2%
1992 73.000.000 -40.27%
1993 223.100.000 67.28%
1994 401.100.000 44.38%
1995 610.500.000 34.3%
1996 555.700.000 -9.86%
1997 515.100.000 -7.88%
1998 633.700.000 18.72%
1999 771.100.000 17.82%
2000 1.196.900.000 35.58%
2001 1.038.400.000 -15.26%
2002 1.590.300.000 34.7%
2003 2.209.800.000 28.03%
2004 2.361.000.000 6.4%
2005 4.044.000.000 41.62%
2006 4.171.000.000 3.04%
2007 4.134.000.000 -0.9%
2008 5.316.000.000 22.23%
2009 5.806.000.000 8.44%
2010 5.207.000.000 -11.5%
2011 4.552.000.000 -14.39%
2012 5.193.000.000 12.34%
2013 5.598.000.000 7.23%
2014 7.552.000.000 25.87%
2015 8.428.000.000 10.39%
2016 9.517.000.000 11.44%
2017 10.513.000.000 9.47%
2018 10.558.000.000 0.43%
2019 8.532.000.000 -23.75%
2020 9.889.000.000 13.72%
2021 8.381.000.000 -17.99%
2022 8.785.000.000 4.6%
2023 2.760.000.000 -218.3%
2023 7.359.000.000 62.49%
2024 2.221.000.000 -231.34%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Amgen Inc. Operating Cashflow
Year Operating Cashflow Growth
1988 -5.900.000
1989 18.700.000 131.55%
1990 13.500.000 -38.52%
1991 219.700.000 93.86%
1992 292.800.000 24.97%
1993 433.000.000 32.38%
1994 531.900.000 18.59%
1995 773.200.000 31.21%
1996 822.600.000 6.01%
1997 902.900.000 8.89%
1998 1.041.500.000 13.31%
1999 1.075.300.000 3.14%
2000 1.634.600.000 34.22%
2001 1.480.200.000 -10.43%
2002 2.248.800.000 34.18%
2003 3.566.600.000 36.95%
2004 3.697.000.000 3.53%
2005 4.911.000.000 24.72%
2006 5.389.000.000 8.87%
2007 5.401.000.000 0.22%
2008 5.988.000.000 9.8%
2009 6.336.000.000 5.49%
2010 5.787.000.000 -9.49%
2011 5.119.000.000 -13.05%
2012 5.882.000.000 12.97%
2013 6.291.000.000 6.5%
2014 8.555.000.000 26.46%
2015 9.077.000.000 5.75%
2016 10.354.000.000 12.33%
2017 11.177.000.000 7.36%
2018 11.296.000.000 1.05%
2019 9.150.000.000 -23.45%
2020 10.497.000.000 12.83%
2021 9.261.000.000 -13.35%
2022 9.721.000.000 4.73%
2023 2.760.000.000 -252.21%
2023 8.471.000.000 67.42%
2024 2.459.000.000 -244.49%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Amgen Inc. Capital Expenditure
Year Capital Expenditure Growth
1988 43.200.000
1989 44.100.000 2.04%
1990 64.900.000 32.05%
1991 117.300.000 44.67%
1992 219.800.000 46.63%
1993 209.900.000 -4.72%
1994 130.800.000 -60.47%
1995 162.700.000 19.61%
1996 266.900.000 39.04%
1997 387.800.000 31.18%
1998 407.800.000 4.9%
1999 304.200.000 -34.06%
2000 437.700.000 30.5%
2001 441.800.000 0.93%
2002 658.500.000 32.91%
2003 1.356.800.000 51.47%
2004 1.336.000.000 -1.56%
2005 867.000.000 -54.09%
2006 1.218.000.000 28.82%
2007 1.267.000.000 3.87%
2008 672.000.000 -88.54%
2009 530.000.000 -26.79%
2010 580.000.000 8.62%
2011 567.000.000 -2.29%
2012 689.000.000 17.71%
2013 693.000.000 0.58%
2014 1.003.000.000 30.91%
2015 649.000.000 -54.55%
2016 837.000.000 22.46%
2017 664.000.000 -26.05%
2018 738.000.000 10.03%
2019 618.000.000 -19.42%
2020 608.000.000 -1.64%
2021 880.000.000 30.91%
2022 936.000.000 5.98%
2023 0 0%
2023 1.112.000.000 100%
2024 238.000.000 -367.23%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Amgen Inc. Equity
Year Equity Growth
1985 80.600.000
1986 84.000.000 4.05%
1987 163.500.000 48.62%
1988 161.900.000 -0.99%
1990 188.100.000 13.93%
1990 188.100.000 0%
1991 531.100.000 64.58%
1992 933.700.000 43.12%
1993 1.172.000.000 20.33%
1994 1.274.300.000 8.03%
1995 1.671.800.000 23.78%
1996 1.906.300.000 12.3%
1997 2.139.300.000 10.89%
1998 2.562.200.000 16.51%
1999 3.023.500.000 15.26%
2000 4.314.500.000 29.92%
2001 5.217.200.000 17.3%
2002 18.286.000.000 71.47%
2003 19.389.100.000 5.69%
2004 19.705.000.000 1.6%
2005 20.451.000.000 3.65%
2006 18.964.000.000 -7.84%
2007 17.869.000.000 -6.13%
2008 20.386.000.000 12.35%
2009 22.667.000.000 10.06%
2010 23.944.000.000 5.33%
2011 19.029.000.000 -25.83%
2012 19.060.000.000 0.16%
2013 22.096.000.000 13.74%
2014 25.778.000.000 14.28%
2015 28.083.000.000 8.21%
2016 29.875.000.000 6%
2017 25.241.000.000 -18.36%
2018 12.500.000.000 -101.93%
2019 9.673.000.000 -29.23%
2020 9.409.000.000 -2.81%
2021 6.700.000.000 -40.43%
2022 3.661.000.000 -83.01%
2023 6.232.000.000 41.25%
2023 7.656.000.000 18.6%
2024 5.925.000.000 -29.22%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Amgen Inc. Assets
Year Assets Growth
1985 93.700.000
1986 96.800.000 3.2%
1987 192.800.000 49.79%
1988 207.100.000 6.9%
1990 308.100.000 32.78%
1990 308.100.000 0%
1991 865.500.000 64.4%
1992 1.374.300.000 37.02%
1993 1.765.500.000 22.16%
1994 1.994.100.000 11.46%
1995 2.432.800.000 18.03%
1996 2.765.600.000 12.03%
1997 3.110.200.000 11.08%
1998 3.672.200.000 15.3%
1999 4.077.600.000 9.94%
2000 5.399.600.000 24.48%
2001 6.443.100.000 16.2%
2002 24.456.300.000 73.65%
2003 26.176.500.000 6.57%
2004 29.221.000.000 10.42%
2005 29.297.000.000 0.26%
2006 33.788.000.000 13.29%
2007 34.639.000.000 2.46%
2008 36.443.000.000 4.95%
2009 39.629.000.000 8.04%
2010 43.486.000.000 8.87%
2011 48.871.000.000 11.02%
2012 54.298.000.000 9.99%
2013 66.125.000.000 17.89%
2014 69.009.000.000 4.18%
2015 71.576.000.000 3.59%
2016 77.626.000.000 7.79%
2017 79.954.000.000 2.91%
2018 66.416.000.000 -20.38%
2019 59.707.000.000 -11.24%
2020 62.948.000.000 5.15%
2021 61.165.000.000 -2.92%
2022 65.121.000.000 6.07%
2023 97.154.000.000 32.97%
2023 90.534.000.000 -7.31%
2024 90.907.000.000 0.41%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Amgen Inc. Liabilities
Year Liabilities Growth
1985 13.100.000
1986 12.800.000 -2.34%
1987 29.300.000 56.31%
1988 45.200.000 35.18%
1990 120.000.000 62.33%
1990 120.000.000 0%
1991 334.400.000 64.11%
1992 440.600.000 24.1%
1993 593.500.000 25.76%
1994 719.800.000 17.55%
1995 761.000.000 5.41%
1996 859.300.000 11.44%
1997 970.900.000 11.49%
1998 1.110.000.000 12.53%
1999 1.054.100.000 -5.3%
2000 1.085.100.000 2.86%
2001 1.225.900.000 11.49%
2002 6.170.300.000 80.13%
2003 6.787.400.000 9.09%
2004 9.516.000.000 28.67%
2005 8.846.000.000 -7.57%
2006 14.824.000.000 40.33%
2007 16.770.000.000 11.6%
2008 16.057.000.000 -4.44%
2009 16.962.000.000 5.34%
2010 19.542.000.000 13.2%
2011 29.842.000.000 34.52%
2012 35.238.000.000 15.31%
2013 44.029.000.000 19.97%
2014 43.231.000.000 -1.85%
2015 43.493.000.000 0.6%
2016 47.751.000.000 8.92%
2017 54.713.000.000 12.72%
2018 53.916.000.000 -1.48%
2019 50.034.000.000 -7.76%
2020 53.539.000.000 6.55%
2021 54.465.000.000 1.7%
2022 61.460.000.000 11.38%
2023 90.922.000.000 32.4%
2023 82.878.000.000 -9.71%
2024 84.982.000.000 2.48%

Amgen Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
57.41
Net Income per Share
5.83
Price to Earning Ratio
54.5x
Price To Sales Ratio
5.54x
POCF Ratio
26.47
PFCF Ratio
31.14
Price to Book Ratio
28.79
EV to Sales
7.27
EV Over EBITDA
19.74
EV to Operating CashFlow
34.76
EV to FreeCashFlow
40.88
Earnings Yield
0.02
FreeCashFlow Yield
0.03
Market Cap
170,70 Bil.
Enterprise Value
224,04 Bil.
Graham Number
38.04
Graham NetNet
-123.8

Income Statement Metrics

Net Income per Share
5.83
Income Quality
2.06
ROE
0.5
Return On Assets
0.05
Return On Capital Employed
0.09
Net Income per EBT
0.9
EBT Per Ebit
0.77
Ebit per Revenue
0.19
Effective Tax Rate
0.1

Margins

Sales, General, & Administrative to Revenue
0.05
Research & Developement to Revenue
0.18
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.6
Operating Profit Margin
0.19
Pretax Profit Margin
0.14
Net Profit Margin
0.13

Dividends

Dividend Yield
0.03
Dividend Yield %
2.8
Payout Ratio
1.5
Dividend Per Share
8.88

Operating Metrics

Operating Cashflow per Share
12
Free CashFlow per Share
10.21
Capex to Operating CashFlow
0.15
Capex to Revenue
0.03
Capex to Depreciation
0.19
Return on Invested Capital
0.08
Return on Tangible Assets
0.07
Days Sales Outstanding
82.1
Days Payables Outstanding
72.88
Days of Inventory on Hand
257.02
Receivables Turnover
4.45
Payables Turnover
5.01
Inventory Turnover
1.42
Capex per Share
1.8

Balance Sheet

Cash per Share
17,32
Book Value per Share
11,03
Tangible Book Value per Share
-79.82
Shareholders Equity per Share
11.03
Interest Debt per Share
122.64
Debt to Equity
10.57
Debt to Assets
0.69
Net Debt to EBITDA
4.7
Current Ratio
1.26
Tangible Asset Value
-42,86 Bil.
Net Current Asset Value
-57,78 Bil.
Invested Capital
60574000000
Working Capital
5,69 Bil.
Intangibles to Total Assets
0.54
Average Receivables
6,86 Bil.
Average Payables
1,95 Bil.
Average Inventory
8359500000
Debt to Market Cap
0.37

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Amgen Inc. Dividends
Year Dividends Growth
2011 1
2012 1 100%
2013 2 0%
2014 2 50%
2015 3 33.33%
2016 4 25%
2017 5 0%
2018 5 20%
2019 6 0%
2020 6 16.67%
2021 7 14.29%
2022 8 0%
2023 9 12.5%
2024 7 -33.33%

Amgen Inc. Profile

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

CEO
Mr. Robert A. Bradway
Employee
26.700
Address
One Amgen Center Drive
Thousand Oaks, 91320-1799

Amgen Inc. Executives & BODs

Amgen Inc. Executives & BODs
# Name Age
1 Mr. Kave Niksefat
Senior Vice President of Global Marketing & Access
70
2 Dr. David M. Reese M.D.
Executive Vice President & Chief Technology Officer
70
3 Mr. Jonathan P. Graham J.D.
Executive Vice President, General Counsel & Secretary
70
4 Ms. Nancy A. Grygiel
Senior Vice President of Worldwide Compliance & Business Ethics and Chief Compliance Officer
70
5 Justin G. Claeys
Vice President of Investor Relations
70
6 Mr. Esteban Santos
Executive Vice President of Operations
70
7 Mr. Matthew C. Busch
Chief Accounting Officer & Vice President of Finance
70
8 Mr. Robert A. Bradway
Chairman, Chief Executive Officer & President
70
9 Mr. Peter H. Griffith
Executive Vice President & Chief Financial Officer
70
10 Mr. Murdo Gordon
Executive Vice President of Global Commercial Operations
70

Amgen Inc. Competitors

Merck & Co., Inc. Logo
Merck & Co., Inc.

MRK

(2.2)
AbbVie Inc. Logo
AbbVie Inc.

ABBV

(2.0)
Johnson & Johnson Logo
Johnson & Johnson

JNJ

(2.8)
Pfizer Inc. Logo
Pfizer Inc.

PFE

(2.5)
Biogen Inc. Logo
Biogen Inc.

BIIB

(2.2)